Brazil phase 3 clinical trial result 50.3% efficacy
78% at the local government announcement last week
Contrasted with clinical results in other countries
Indonesia 65.3%, Turkey 91.3%
On the 13th, medical staff in Surabaya in the northeastern part of Java Island, Indonesia, are checking the Corona 19 vaccine of Chinese pharmaceutical company Sinobac. Surabaya/AFP Yonhap News
Controversy over the efficacy of the Chinese pharmaceutical company Sinobac’s COVID-19 vaccine is amplifying. This is because reports of efficacy results are mixed in different countries that have conducted phase 3 clinical trials. Summarizing the reports on the 13th and so on, Sinobac’s Corona 19 vaccine, Coronavirus, managed to exceed 50% of the efficacy as a result of a phase 3 clinical trial conducted in Brazil. The 50% efficacy is the lowest standard for approval for use recommended by the World Health Organization (WHO). The Bhutantang Research Center in Sao Paulo, which led the coronavirus phase 3 test, held a press conference on the 12th (local time) and said, “The preventive effect of coronavirus was 50.3%.” “It is safe and effective, and all the requirements for urgent use approval I was satisfied.” The research center initially announced that it would announce the final results to 11,000 volunteers, including medical staff, immediately after completing phase 3 clinical trials for coronavirus in the middle of last month. The lab’s announcement on the efficacy of the coronavirus differs significantly from the announcement by the state government of Sao Paulo last week. At the time, the health authorities of the state of Sao Paulo said that the efficacy of the coronavirus reached 78%, and from the 25th to the end of March, it was planning to immunize 9 million people, including medical staff and the elderly over 60 years old. The results of interim announcements in other countries that are conducting phase 3 clinical trials for coronavirus also vary widely. Indonesian health officials announced on the 11th that Wang gave approval for emergency use of coronavirus in line with the visit of the Chinese foreign minister, and the vaccine’s efficacy was 65.3%. Indonesia has already imported 3 million doses of coronavirus, and President Joko Widodo personally stepped out as the first inoculation this morning to emphasize safety. On the other hand, the Turkish side said on the 24th of last month that the efficacy of coronavirus was 91.3%. “It seems difficult to generalize test results such as efficacy, as there were only 1600 and 1300 clinical trial participants in Indonesia and Turkey, respectively.” The Synobac side has not made any official comments on the results of phase 3 clinical trials so far. Correspondent in Beijing/Inhwan Jung